psychiatry
Eating Disorder Assessment
Medical risk stratification in anorexia nervosa and management pathway
Source: NICE CG9 2017 / MARSIPAN
Step 1 of ~6
info
Eating Disorder Assessment
Assess: BMI (critical <13 kg/m²), rate of weight loss, medical complications, psychiatric comorbidity, insight. MARSIPAN risk rating (LOW/MEDIUM/HIGH/VERY HIGH).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Silicone Gel / Sheeting (Scar Management) · Medical Device / Topical Scar Treatment
- Lisdexamfetamine · CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Sodium phenylbutyrate · Ammonia scavenger (alternative pathway)
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF
Decision support only. Always apply local guidelines and clinical judgement.